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Abstract In addition to its’ established metabolic and
cardioprotective effects, glucagon-like peptide-1 (GLP-1)
reduces post-infarction heart failure via preferential actions
on the extracellular matrix (ECM). Here, we investigated
whether the GLP-1 mimetic, exendin-4, modulates cardiac
remodelling in experimental diabetes by specifically tar-
geting inflammatory/ECM pathways, which are character-
istically dysregulated in this setting. Adult mice were
subjected to streptozotocin (STZ) diabetes and infused with
exendin-4/insulin/saline from 0 to 4 or 4–12 weeks.
Exendin-4 and insulin improved metabolic parameters in
diabetic mice after 12 weeks, but only exendin-4 reduced
cardiac diastolic dysfunction and interstitial fibrosis in
parallel with altered ECM gene expression. Whilst
myocardial inflammation was not evident at 12 weeks,
CD11b-F4/80?? macrophage infiltration at 4 weeks was
increased and reduced by exendin-4, together with an
improved cytokine profile. Notably, media collected from
high glucose-treated macrophages induced cardiac fibrob-
last differentiation, which was prevented by exendin-4,
whilst several cytokines/chemokines were differentially
expressed/secreted by exendin-4-treated macrophages,
some of which were modulated in STZ exendin-4-treated
hearts. Our findings suggest that exendin-4 preferentially
protects against ECM remodelling and diastolic dysfunc-
tion in experimental diabetes via glucose-dependent mod-
ulation of paracrine communication between infiltrating
macrophages and resident fibroblasts, thereby indicating
that cell-specific targeting of GLP-1 signalling may be a
viable therapeutic strategy in this setting.
Keywords Glucagon-like peptide-1  Experimental
diabetes  Cardiac remodelling  Extracellular matrix 
Inflammation
Introduction
Diabetes is particularly characterised by increased risk of
chronic heart failure (CHF), largely secondary to hyper-
tension or ischemia, which carries a particularly poor
prognosis, although the disease itself is an independent risk
factor for CHF with some patients developing cardiac
dysfunction in the absence of such etiological factors [4,
10]. Whilst the existence of a distinct diabetic cardiomy-
opathy remains controversial, it is widely held that the
diabetic heart undergoes characteristic structural changes
independent of ischemia, which undoubtedly underlie
enhanced susceptibility to stress [36]. Indeed, a prominent
feature is marked collagen accumulation linked with
extensive extracellular matrix (ECM) changes, which is the
most likely factor underlying cardiac stiffness and sub-
clinical diastolic dysfunction occurring in *60 % of
optimally controlled diabetic patients [13, 38]. This is
accompanied by marked changes in cardiomyocyte biology
and myocardial inflammation, which is a key driver of
cardiac remodelling in this setting, particularly in regard to
the ECM [8, 16, 46].
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Over the last few years, our group and others have
focused on the cardiovascular actions of glucagon-like
peptide-1 (GLP-1), whose established metabolic effects
have been clinically exploited for glycemic control in type
2 diabetes [14, 41]. It is well known that GLP-1 is an
important regulator of normal cardiovascular physiology
and also exerts beneficial effects in cardiovascular disease
both in the presence or absence of diabetes [28, 41].
Indeed, GLP-1 receptor (GLP-1R) agonists and dipeptidyl
peptidase-4 (DPP-4) inhibitors, which increase endoge-
nous GLP-1, are widely reported to protect cardiomy-
ocytes from acute ischemia and improve functional
recovery after myocardial infarction (MI) [6, 42].
Importantly, in the context of CHF, two studies have now
demonstrated that GLP-1 analogues also exert beneficial
actions on post-MI survival and cardiac structure/function
in rodent models independent of acute infarct-limiting and
metabolic effects [12, 23], suggesting that GLP-1 may
directly protect against chronic cardiac remodelling.
Notably, our group has recently built on these findings to
show that the GLP-1 mimetic, exendin-4, significantly
reduces progression of post-MI remodelling in normo-
glycemic mice via specific actions on myocardial
inflammation and the ECM [34], which are characteristic
features of diabetes [8]. Indeed, further to the seemingly
complex pleiotropic actions of GLP-1 signalling and
disappointing results of recent DPP-4 inhibitor cardio-
vascular trials, it is evident that selective targeting of
specific remodelling components may be required to
realise the clear therapeutic potential of GLP-1 in this
setting [41]. The aim of this study was therefore to
investigate the likely beneficial effects of GLP-1 in this
setting, testing the hypothesis that exendin-4 modulates
development and progression of adverse cardiac remod-
elling in experimental diabetes by specifically targeting
inflammatory and ECM components. Notably, we report
for the first time that exendin-4 mediates novel cell-
specific glucose-dependent actions on paracrine signalling
between infiltrating macrophages and resident fibroblasts,
which appear to underlie direct protection against the




Male C57BL/6J mice (8–12 weeks; Harlan UK) were used
throughout this study and were housed under constant
climatic conditions with free access to food and water. All
experimental procedures were performed in accordance
with the Guidance on the Operation of the Animals
(Scientific Procedures) Act, 1986 (UK) and were approved
by the Queen’s University Belfast Animal Welfare and
Ethical Review Body.
Experimental model
Mice were randomised into diabetic and non-diabetic
groups at 8–12 weeks of age, which received five consec-
utive daily injections of streptozotocin (STZ, 55 mg/kg i.p.
in citrate buffer, pH 4.5; Sigma-Aldrich, Poole, UK) or
vehicle, respectively. STZ-injected mice were confirmed as
diabetic if blood glucose concentrations [15 mmol/L
(Breeze2, Bayer, Newbury, UK) were evident at 2 weeks.
Diabetic and non-diabetic mice were randomly assigned
for chronic infusion with either the DPP-4 resistant GLP-1
mimetic, exendin-4 (at a concentration employed in pre-
vious in vivo studies; 25 nmol/kg/day; GL Biochem,
average purity 90 %) [34], or saline control via an osmotic
minipump (Model 1004, Alzet, Cupertino, CA, USA) for
either 4 or 8 weeks. For the chronic 8-week treatment
study, exendin-4 or vehicle control was administered from
4 weeks after STZ induction, when significantly elevated
blood glucose levels were evident, prior to terminal
assessment at 12 weeks (Online Resource 1). In this study,
a comparator group of diabetic mice received twice daily
insulin injections (8 mU/g/day i.p.; Humulin, Eli Lilly,
Basingstoke, UK); dose determined in pilot study (Online
Resource 2) which induced equivalent reductions in blood
glucose versus exendin-4 [27]. For the acute treatment
study, animals received exendin-4 or vehicle control 1 day
prior to STZ induction and thereafter for a period of
4 weeks (Online Resource 3). At the end of each protocol,
animals were either terminally anaesthetised (2 % isoflu-
rane/oxygen) and hearts arrested in diastole by injection of
10 % KCl, excised and fixed in 10 % neutral-buffered
formalin solution, or sacrificed by sodium pentobarbitone
overdose (200 mg/kg i.p.) prior to excision of hearts which
were frozen in liquid nitrogen or subjected to flow
cytometry.
Assessment of plasma lipids and HbA1c
Terminal blood samples were collected by cardiac puncture
(after a fasting period of 5 h) into heparinised tubes and
centrifuged at 10,000g for 10 min to obtain separate cell
and plasma fractions. Plasma samples were analysed using
enzymatic assay kits (Analox Instruments Ltd, London,
UK) for cholesterol (GMRD-084 using cholesterol ester-
ase) and triglyceride (GMRD-195 using lipase) which were
detected on a GM7 Micro-Stat Analyser (Analox Instru-
ments Ltd). Glycated haemoglobin, HbA1c, was assessed
in cell fractions using a commercially available assay kit
(Helena Biosciences, Gateshead, UK), measuring
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absorbance at 415 nm on a microplate reader (Safire,
Tecan, Mannedorf, Switzerland) and was expressed as % of
total haemoglobin.
Echocardiography
Mice were anaesthetised with 1.5 % isofluorane/oxygen,
placed on a warming pad, and imaged in the supine posi-
tion using a Vevo770 ultrasound system with high-fre-
quency 45 MHz RMV707B scanhead (VisualSonics,
Amsterdam, The Netherlands). M-mode parasternal short-
axis scans at papillary muscle level were used to quantify
left ventricular (LV) end-diastolic (LVEDD) and end-sys-
tolic diameters (LVESD) from which percent fractional
shortening was calculated using the equation
(LVEDD - LVESD)/LVEDD 9 100. Pulse-wave Dop-
pler was used to assess mitral valve flow (E/A ratio), LV
isovolumetric relaxation time and myocardial performance
index, as reliable measures of diastolic function.
Histology and immunohistochemistry
Following excision, hearts were weighed and measure-
ments normalised to tibial length. All histological analyses
were performed using paraffin-embedded LV sections
(5 lm). Cardiomyocyte cross-sectional area was deter-
mined by H&E staining, analysing cells with centrally
located nuclei. Cardiac interstitial fibrosis was assessed by
picrosirius red staining (0.1 % w/v), excluding coronary
vessels and perivascular regions. Data were quantified by
digital image analysis (NIS-Elements, Nikon, London, UK)
with the observer blinded to sample identity. Immunocy-
tochemistry for CD45 and F4/80 was performed using rat
polyclonal (553076, 1:200; BD Bioscience, Oxford, UK)
and rat monoclonal (ab6640, 1:200; Abcam, Cambridge,
UK) antibodies, respectively, followed by secondary rabbit
anti-rat IgG (P0450, 1:100; Dako, Ely, UK) staining, using
diaminobenzidine as the chromogen and nuclear counter-
staining with haematoxylin.
Pancreases were harvested into 10 % neutral-buffered
formalin, paraffin-embedded, and sectioned (5 lm) prior to
staining for glucagon (ab92517, 1:500; Abcam) and insulin
(C27C9, 1:200; Cell Signaling, Danvers, MA, USA) using
rabbit monoclonal antibodies, followed by incubation with
donkey anti-rabbit IgG (ab98502, 1:500; Abcam). Sec-
tions were imaged on an epifluorescence microscope
(Eclipse 80i, Nikon, London, UK) with the FITC anti-
bodies excited at 488 nm and using an emission filter at a
wavelength of 530 nm. Data were quantified by blinded
digital image analysis (NIS-Elements, Nikon, London, UK)
with the observer blinded to sample identity, and were
expressed as % b-cell area and islet number/area per mm2
pancreas.
RNA isolation and quantitative RT-PCR analysis
Total RNA was extracted from LV homogenate or cells
using TRI reagent (Sigma-Aldrich, Poole, UK) and cDNA
was synthesised by reverse transcription (Life Technolo-
gies, Paisley, UK). mRNA expression of procollagen IIIaI,
MMP-2, MMP-9, TIMP-2, IL-1b, IL-6, IL-10, a-SMA,
CTGF, procollagen IaI, TGF-b1, IL-1ra, CXCL10, MIP-
1a, MIP-1b, MIP-2, TIMP-1, CD11b, CCL2, and bFGF
was analysed by real-time reverse transcription-polymerase
chain reaction (RT-PCR) using fluorescent SYBR Green
(Prism 7300, Life Technologies, Paisley, UK) and b-actin
or GAPDH was used for normalisation (whose expression
was shown to remain unaltered between experimental
groups in both cells and tissues; GeNorm, Primer Design,
Southampton, UK) by the comparative Ct method [49].
Primer sequences are shown in Online Resource 4.
Flow cytometry
Hearts were collected and the LV separated into RPMI-
1640 (Sigma-Aldrich, Poole, UK) and minced in the
presence of collagenase type II (1 mg/mL; Invitrogen,
Paisley, UK) and DNAse (40 ng/mL; Sigma-Aldrich,
Poole, UK), prior to addition of EDTA to prevent cell
clumping. After red blood cell lysis using ACK buffer,
cells were blocked in 1 % FBS before incubation with the
following fluorochrome-conjugated antibody cocktails to
assess surface inflammatory cell marker expression by flow
cytometry: CD45 (30-F11, 1:250), CD4 (RM4-5, 1:200),
CD8 (53–6.7, 1:200), MHC class II (AF6-120.1, 1:200),
B220 (RA3-6B2, 1:200), CD11b (M1/70, 1:200), CD117
(2B8, 1:100; all BD Biosciences, Oxford, UK) and F4/80
(MHA497PE, 1:200; AbD Serotec, Oxford, UK). Data
were collected on a FACS Canto II flow cytometer (BD
Biosciences, Oxford, UK) and analysed using FlowJo
software (Tree Star Inc, Ashland, USA).
Murine bone marrow-derived macrophage culture
Murine bone-marrow derived macrophages (BMDM) were
isolated from separate cohorts of untreated C57BL/6J mice,
as previously described [34]. Briefly, mice were euthanised
(sodium pentobarbitone, 200 mg/kg i.p.) and their femurs
isolated before bone marrow cells were flushed out with
supplemented DMEM (10 % FBS, and 100 U/mL peni-
cillin and 100 mg/mL streptomycin). Cells were cen-
trifuged and resuspended in ACK lysis buffer (to destroy
any contaminating red blood cells) prior to centrifugation
and resuspension in DMEM supplemented with L929 cell
supernatant (1:6) containing macrophage colony-stimulat-
ing factor to induce differentiation. Cells were then seeded
into a 150 mm tissue culture plate and after 4 days were
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scraped into DMEM, centrifuged, and seeded 1:3 into tis-
sue culture plates containing L929 supernatant-supple-
mented DMEM. After 8 days, cells were split into 6-well
plates, each containing 1 million cells, prior to incubation
in DMEM without L929 supernatant in the presence of
normal (5 mmol/L) or high (25 mmol/L) glucose with or
without exendin-4 (1 nmol/L) for 72 h. RNA and cDNA
were then prepared for mRNA expression analysis, as
described previously, whilst the supernatant (conditioned
media) was collected, filtered with a 22 lm filter, and
stored at -80 C for subsequent studies or analysis.
Murine cardiac fibroblast culture
Murine cardiac fibroblasts were also isolated from
untreated C57BL/6J mice, as previously described [34].
Briefly, five mice per isolation were euthanised (sodium
pentobarbitone, 200 mg/kg i.p.) and heparinised before
their hearts were removed and ventricles isolated prior to
mincing and mixing with 4 mL LiberaseTM solution
(Roche, Burgess Hill, UK) at 37 C for 8 min. The
supernatant was then removed and the process was repe-
ated a further three times with the undigested tissue prior to
filtration, centrifugation, and resuspension of the pellet in
supplemented DMEM (10 % FBS, 20 mmol/L L-glu-
tamine, 100 U/mL penicillin and 100 mg/mL strepto-
mycin). Cells were then transferred to a 1 % gelatin-coated
T75 flask with 10 mL DMEM at 37 C and cultured in a
humidified atmosphere of 5 % CO2 for approximately
7 days until 90 % confluent, when they were trypsinised,
centrifuged, and reseeded at 1:2 for expansion. At passage
2, cardiac fibroblasts were treated with conditioned media
harvested from BMDM (as detailed above), with or without
TGF-b (5 ng/mL, to induce myofibroblast differentiation),
prior to preparation of RNA/cDNA and real-time RT-PCR
analysis of mRNA expression, as described previously.
Proteome array
Cytokine and chemokine protein expression was assessed
in BMDM-conditioned media samples pooled from four
preparations using a Proteome ProfilerTM antibody array
(R&D Systems, Abingdon, UK), as per the manufacturer’s
instructions.
Statistical analysis
Data are expressed as mean ± SEM and were analysed by
either a one-way or two-way ANOVA followed by a
Bonferroni’s multiple comparison test, using GraphPad
Prism software (La Jolla, USA). P\ 0.05 was considered
to be statistically significant.
Results
Metabolic changes after 12 weeks STZ diabetes
Serial STZ injections resulted in progressive increases in
fasting blood glucose which were maximal by 3 weeks
(vehicle control, 9.1 ± 0.5; STZ control,
23.5 ± 1.6 mmol/L; n = 6–19, P\ 0.001) and sustained
thereafter. Initially, mice were continuously infused with
exendin-4 from 4 to 12 weeks (Online Resource 1), which
resulted in significant reduction of blood glucose, HbA1c,
and plasma triglycerides versus STZ controls, whilst
cholesterol remained unaltered (Fig. 1a–d). To allow sep-
aration of indirect and direct actions of exendin-4 on the
diabetic heart, an insulin comparator group was included to
mimic the observed metabolic effects. Indeed, daily
injection of STZ mice with insulin, at a dose determined by
a pilot study (Online Resource 2), produced equivalent
reductions in blood glucose, HbA1c, and plasma triglyc-
erides versus exendin-4 (Fig. 1a–d). Normal pancreatic
morphology, indicated by tightly packed insulin-stained b
cells surrounded by a glucagon-positive a-cell ‘‘halo’’
(Fig. 1e), was markedly altered in STZ diabetic mice,
reflected by reduced b-cell area and islet number/area with
a disordered appearance, effects which were partially res-
cued by both exendin-4 and insulin (Fig. 1f–h).
Cardiac function after 12 weeks STZ diabetes
No differences in echocardiographic structure and systolic
function were observed between groups, indicated by LV
end-systolic/diastolic dimensions and fractional shortening,
whilst heart rate also remained unchanged (Table 1).
However, diastolic dysfunction evident in STZ diabetic
mice was markedly improved by exendin-4, indicated by
increased mitral valve E/A and normalisation of LV iso-
volumetric relaxation time and myocardial performance
index, but notably, these parameters were not altered by
insulin.
Cardiac remodelling
Neither exendin-4 nor insulin had any effect on body
weight, cardiac morphometrics or cardiomyocyte cross-
sectional area in STZ mice after 12 weeks (Table 1; Online
Resource 5). However, cardiac interstitial fibrosis was
markedly increased in STZ control hearts, which, consis-
tent with the diastolic function data, was attenuated by
exendin-4, but not insulin (Fig. 2a). Similarly, mRNA
expression of several important ECM genes (procollagen
IIIaI, MMP-2, and TIMP2) was significantly modulated in
STZ mice by exendin-4-but not insulin (Fig. 2b–e).
1 Page 4 of 13 Basic Res Cardiol (2016) 111:1
123
Myocardial inflammation
Although exendin-4 markedly improved STZ-induced
ECM remodelling and diastolic dysfunction, which may be
largely driven by inflammation [36], myocardial infiltration
of CD45? leukocytes and F4/80? macrophages were not
significantly different between groups after 12 weeks
(Fig. 2f, g), whilst no effect of exendin-4 on pro-inflam-
matory cytokines was observed (Fig. 2h, i). A pilot study
was subsequently performed to characterise the time course
of STZ-induced inflammation by flow cytometry (Online
Resource 6). Notably, significant myocardial inflammatory
cell infiltration was evident at 4 weeks (but not 8 or
12 weeks), indicated by increased CD11b-F4/80?? mac-
rophages and CD117? mast cells, with the former con-
tributing *5 times more cells (although total CD45? cells
were unaltered). As it appeared that acute myocardial
inflammation is particularly important in STZ diabetes,
which may drive subsequent fibrosis and diastolic dys-
function, a short-term model was employed in mice which
were infused with exendin-4 1 day prior to STZ induction
and for 4 weeks (Online Resource 3). Indeed, myocardial
infiltration of CD11b-F4/80?? macrophages (but not
CD45? leukocytes; analysed using ten high power fields
per section) was significantly increased in STZ hearts after
4 weeks, and clearly reduced by exendin-4, although
numbers of CD3–CD4–CD8??? T cells, B220? B cells,
and MHC class II? antigen-presenting cells remained
similar between groups (Table 2). Whilst further
immunohistochemical analysis demonstrated marked
CD45? leukocyte infiltration in STZ mice which was
unaltered by exendin-4 (Fig. 3a), significantly increased
F4/80? macrophages in diabetic hearts were reduced in
exendin-4-treated mice (Fig. 3b). Similarly, increased pro-
Fig. 1 Effect of exendin-4 and insulin on metabolic characteristics
after 12 weeks STZ diabetes. Terminal blood assessment of a plasma
glucose (n = 5–18), b HbA1c (n = 6–13), c triglyceride (n = 6–14)
and d cholesterol (n = 6–11). e Representative images of pancreatic
islets stained with insulin and glucagon, with quantification of f b-cell
area, g number of islets and h islet area (all n = 6–13). White columns
control; black columns exendin-4; grey columns insulin; mean ± -
SEM. *P\ 0.05; **P\ 0.01; ***P\ 0.001, versus corresponding
vehicle; P\ 0.05; P\ 0.01; P\ 0.001 versus STZ control
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inflammatory IL-1b and IL-6 expression in STZ hearts was
decreased by exendin-4, whilst anti-inflammatory IL-10
expression was induced by exendin-4 (Fig. 3c–e). Indeed,
consistent with the 12-week model, diabetic mice treated
with exendin-4 for 4 weeks coincident with STZ induction
demonstrated preserved diastolic dysfunction, indicated by
elevated mitral valve E/A (Online Resource 7), suggesting
that the cardioprotective actions of exendin-4 may occur
via modulation of acute inflammation.
Isolated cell studies
Our previous study indicated that exendin-4 does not
directly influence murine cardiac fibroblasts, but may
rather modulate the macrophage secretome [34], high-
lighting paracrine communication as a likely mechanism
underlying improved ECM remodelling and diastolic
function in exendin-4-treated STZ mice. We therefore
performed a series of studies to investigate effects of
exendin-4 on BMDM mRNA expression, secretion, and
paracrine effects on cardiac fibroblasts under both normal
and high glucose conditions. Interestingly, conditioned
media from BMDM maintained in high glucose for 72 h
induced myofibroblast differentiation in unstimulated cells,
indicated by increased expression of a-SMA and CTGF, an
effect not seen in normoglycemia but which was accentu-
ated in the presence of TGF-b, evident by further induction
of a-SMA and CTGF together with TGF-b1 (Fig. 4a–d).
Notably, these changes were virtually abolished in fibrob-
lasts incubated in conditioned media from exendin-4-trea-
ted BMDM. To identify potential paracrine mediators,
BMDM-conditioned media pooled from each experimental
group was analysed by proteome array, which identified
several cytokines/chemokines differentially secreted by
exendin-4-treated cells in high glucose (Fig. 4e). Intracel-
lular mRNA expression of key cytokines was also induced
in high glucose-treated BMDM (IL-1b, IL-10, CD11b, and
bFGF) and further increased by exendin-4 (Fig. 5). Nota-
bly, mRNA expression of one of the candidate BMDM-
secreted cytokines/chemokines identified by the proteome
array, CXCL10, was significantly modulated in LV tissue
from STZ exendin-4-treated mice at 4 weeks (Fig. 6b),
together with IL-1b and IL-10 (Fig. 3c, e, which were also
induced by high glucose; Fig. 5a, b), highlighting their
potential importance in vivo, whilst others tended towards
change (e.g. MIP-2; Fig. 6e).
Discussion
This is the first study to report specific effects of the GLP-1
mimetic, exendin-4, on adverse cardiac remodelling in
experimental diabetes, which occur at least partly inde-
pendently of its established glucose-lowering actions.
Table 1 Effect of exendin-4 and insulin on cardiac function and morphometry after 12 weeks STZ diabetes
Vehicle STZ
Control Exendin-4 Control Exendin-4 Insulin
Echocardiography data
n 6 6 16 10 6
Heart rate (bpm) 434 ± 13 430 ± 31 415 ± 10 427 ± 18 415 ± 8
LVESD (mm) 2.64 ± 0.05 2.44 ± 0.07 2.47 ± 0.06 2.62 ± 0.05 2.64 ± 0.06
LVEDD (mm) 3.77 ± 0.09 4.05 ± 0.04 3.78 ± 0.07 3.91 ± 0.08 3.92 ± 0.07
Fractional shortening (%) 37.0 ± 1.1 32.7 ± 1.0 34.1 ± 0.8 34.4 ± 0.9 35.8 ± 1.2
MV E/A 2.11 ± 0.05 2.06 ± 0.04 1.21 ± 0.06*** 1.58 ± 0.05***, 1.29 ± 0.08
IVRT (ms) 16.4 ± 1.7 17.9 ± 0.6 21.4 ± 1.3 15.6 ± 1.9 20.3 ± 0.9
MPI 0.51 ± 0.03 0.57 ± 0.04 0.62 ± 0.02* 0.51 ± 0.04 0.62 ± 0.03
Morphometric data
n 6 6 19 12 6
Body weight (g) 28.2 ± 1.2 27.9 ± 0.6 25 ± 0.6*** 25.3 ± 0.9** 26.5 ± 0.3
Tibial length (mm) 18.5 ± 0.1 19.1 ± 0.2 18.4 ± 0.2 18.6 ± 0.2 18.8 ± 0.2
LV weight (mg) 81.8 ± 5.4 90.2 ± 4.7 74.9 ± 2.3 72.4 ± 2.2** 77.9 ± 4.4
LV weight/tibial length 4.33 ± 0.33 4.71 ± 0.22 3.91 ± 0.13* 3.84 ± 0.11 4.15 ± 0.22
Mean ± SEM
LVESD LV end-systolic diameter, LVEDD LV end-diastolic diameter, MV E/A mitral valve E/A ratio, IVRT isovolumetric relaxation time, MPI
myocardial performance index
* P\ 0.05; ** P\ 0.01; *** P\ 0.001 versus corresponding vehicle
 P\ 0.05;  P\ 0.001 versus STZ control
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Exendin-4 preferentially reduced ECM remodelling and
diastolic dysfunction, which was associated with specific
attenuation of acute myocardial macrophage infiltration
and altered inflammatory gene expression. Notably, com-
plementary cell studies revealed direct anti-inflammatory
effects of exendin-4 on BMDM under both normoglycemic
and hyperglycemic conditions, and highlighted novel glu-
cose-dependent paracrine inhibition of cardiac fibroblast
differentiation, suggesting that the cardioprotective actions
of exendin-4 in diabetes may occur via specific modulation
of infiltrating macrophages.
The rationale for this study was based on recent reports
that GLP-1 analogues improve post-MI remodelling in
rodent models and our own work highlighting specific
modulation of ECM and inflammatory components [12, 23,
34], which are characteristic features of the diabetic heart.
Indeed, this supposition is supported by reports that cardiac
GLP-1R expression may be less ubiquitous than previously
thought and the persistence of liraglutide-induced cardio-
protection in mice with cardiomyocyte-specific GLP-1R
deletion [41, 44], suggesting that the cardiac actions of
GLP-1 may be mediated by an alternative cell type. To
Fig. 2 Effect of exendin-4 on ECM remodelling and myocardial
inflammation after 12 weeks STZ diabetes. a Representative LV
sections stained with picrosirius red to assess interstitial fibrosis and
quantification data (n = 6–13). b–e, h, i mRNA expression of ECM
genes/cytokines in LV tissue (n = 5–8). f–g Quantification of LV
sections probed for CD45 and F4/80 to assess leukocyte and
macrophage infiltration, respectively (n = 4–8). White columns
control; black columns exendin-4; grey columns insulin; mean ± -
SEM. *P\ 0.05; **P\ 0.01; ***P\ 0.001 versus corresponding
vehicle; P\ 0.05; P\ 0.01 versus corresponding control
Table 2 Flow cytometry
characterisation of cardiac
inflammatory cells after
4 weeks STZ diabetes
Vehicle STZ
Control Exendin-4 Control Exendin-4
CD45?/100,000 total cells 105 ± 10 139 ± 21 174 ± 18 205 ± 25
CD11b-F4/80??/CD45? cells (%) 13.7 ± 0.9 12.2 ± 0.7 20.6 ± 1.4*** 15.4 ± 1.1
CD4?/CD45? cells (%) 6.6 ± 0.9 8.1 ± 0.7 7.0 ± 0.3 7.1 ± 1.1
CD8?/CD45? cells (%) 5.4 ± 0.3 6.5 ± 0.3 5.7 ± 0.3 8.3 ± 1.8
MHCII?/CD45? cells (%) 58.9 ± 2.4 52.2 ± 2.4 55.9 ± 2.2 54.1 ± 1.2
B220?/CD45? cells (%) 48.6 ± 4.1 44.7 ± 1.4 47.1 ± 3.2 47.8 ± 2.3
Each value represents relative frequency versus total CD45? cells. Mean ± SEM (n = 6–8)
*** P\ 0.001 versus corresponding vehicle
 P\ 0.05 versus STZ control
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address this key question, we chose to employ an estab-
lished murine model of experimental STZ diabetes using a
combined in vivo/ex vivo/in vitro approach. Whilst a type
2 model may be more clinically relevant, it should be noted
that, of these, only db/db mice show discernible cardiac
dysfunction after a prolonged period whilst data analysis in
such models may be confused by the cardiovascular effects
of obesity and/or dysfunctional leptin signalling, so STZ
diabetes (which shares common features with type 2 dia-
betes) was considered to be the most appropriate choice for
our study [1, 3, 5, 37]. Importantly, the employed low-dose
STZ induction protocol promotes an immune b-cell
response causing progressive b-cell damage, leading to
local inflammation and insulitis as seen in clinical diabetes
[7], thereby avoiding potentially confounding STZ toxicity
associated with other models. STZ diabetes is also asso-
ciated with significant cardiac remodelling at 12 weeks, by
which time diastolic dysfunction and fibrosis are clearly
evident, which are characteristic of both type 1 and type 2
diabetes, and this model has been widely employed for
such studies [18, 20, 46]. Notably, exendin-4 was infused
from 4 weeks, at a concentration comparable to previous
experimental studies [32, 34], once elevated glucose levels
had been achieved, to further reflect the likely clinical
scenario.
The initial clinical manifestation of cardiac dysfunction
in diabetes is often asymptomatic and only emerges once
patients present with ischemic or hypertensive CHF [36].
Despite significant advances in elucidation of the under-
lying pathogenesis, separation of the undoubted direct
cardiac effects of diabetes and the indirect contribution of
associated cardiovascular risk factors has remained diffi-
cult, which is critical as 60 % of optimally managed dia-
betic patients have diastolic dysfunction [13, 30]. Indeed,
GLP-1 exerts numerous extra-pancreatic actions, under
both physiological and pathophysiological conditions,
including reduction of diabetic and cardiovascular risk
factors [14, 41]. However, both GLP-1 analogues and DPP-
4 inhibitors confer protection against cardiac dysfunction/
remodelling associated with experimental MI, dilated car-
diomyopathy, and hypertensive CHF in the absence of
metabolic changes [15, 23, 31, 33], indicating that GLP-1
exerts direct cardiac effects. To dissect such actions of
exendin-4 in experimental diabetes, we performed com-
prehensive metabolic assessment of our animals and also
included an insulin comparator group. Blood glucose,
Fig. 3 Effect of exendin-4 on myocardial inflammation after 4 weeks
STZ diabetes. Representative LV sections probed for a CD45 and
b F4/80, to assess leukocyte and macrophage infiltration, respectively,
together with mean quantification data analysing ten high power fields
per section (n = 5–6). c–e cytokine mRNA expression in LV tissue
(n = 5–7). White columns control; black columns exendin-4;
mean ± SEM. *P\ 0.05; ***P\ 0.001 versus corresponding vehi-
cle; P\ 0.05 versus STZ control
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HbA1c, and triglycerides were elevated in STZ animals
and reduced to comparable levels by exendin-4 and insulin.
Pancreatic morphology was also obviously impaired by
STZ (although the low-dose model does not completely
ablate b cells), and both exendin-4 and insulin promoted
partial regeneration, which is consistent with previous
reports and may occur due to mobilisation of progenitor
cell populations [7, 11, 48]. Notably, exendin-4 markedly
Fig. 4 Effect of exendin-4 on paracrine communication between
bone marrow-derived macrophages and cardiac fibroblasts. a–
d mRNA expression of myofibroblast differentiation markers in
basal and TGF-b-stimulated cardiac fibroblasts incubated in condi-
tioned media from BMDM treated with normal/high glucose with/
without exendin-4 for 24 h (n = 6). e Cytokine/chemokine array
blots from BMDM-conditioned media with quantification of protein
expression (pooled from four preparations). White columns normal
glucose control; black columns normal glucose exendin-4; light grey
columns high glucose control; dark grey columns high glucose
exendin-4; mean ± SEM. **P\ 0.01; ***P\ 0.001 versus corre-
sponding vehicle; P\ 0.01; P\ 0.001 versus corresponding
glucose control; #P\ 0.05; ###P\ 0.001 versus corresponding
normal glucose
Fig. 5 Effect of exendin-4 on mRNA expression in bone marrow
derived macrophages incubated in normal and high glucose for 72 h.
Real-time RT-PCR analysis of transcript levels of a IL-1b, b IL-10,
c CD11b, d CCL2, e bFGF, and f MMP-9 were analysed (n = 4).
White columns control; black columns exendin-4; mean ± SEM.
**P\ 0.01; ***P\ 0.001 versus corresponding vehicle, P\ 0.05;
P\ 0.01, versus normal glucose exendin-4
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improved both diastolic function (as indicated by mitral
valve E/A, LV isovolumetric relaxation time, and
myocardial performance index) and ECM remodelling in
STZ mice, whereas insulin-treated animals, which
demonstrated similar metabolic benefits (and indeed tended
to exhibit lower blood glucose and better pancreatic mor-
phology), displayed equivalent cardiac dysfunction/re-
modelling to STZ controls, strongly suggesting that
exendin-4 exerts direct cardioprotective actions in diabetes.
Consistent with our previous study, exendin-4 (and
insulin) had no effect on cardiac morphometry or car-
diomyocyte area in diabetic animals, although both body
weight and LV mass were reduced by STZ, which are
recognised features of this model [34, 45]. Since ECM
remodelling and fibrosis are the natural consequence of
inflammation, which is particularly evident in diabetes [8,
46], we primarily focused on characterising effects of
exendin-4 on the myocardial inflammatory response in
STZ mice. As cardiac inflammation had resolved by
12 weeks, and subsequent flow cytometry analysis
demonstrated early and specific infiltration of CD11b-F4/
80?? macrophages and CD117? mast cells in diabetic
hearts, further studies were conducted in which exendin-4
was infused concomitant with STZ induction to investigate
acute inflammatory effects. In this case, exendin-4 induced
marked attenuation of macrophage infiltration, whilst mast
cells were unaffected, suggesting that the observed effects
on myocardial function/remodelling in the 12-week model
may occur secondary to specific modulation of acute
macrophage function (although the source of these cells
cannot be concluded from our data). Indeed, macrophage
infiltration is reported to be increased in diabetic hearts,
where these cells display a switch from a M2 anti-inflam-
matory towards a M1 pro-inflammatory profile, together
with elevated cytokine levels [35, 43]. Notably, in addition
to our previous work highlighting macrophage-specific
effects of exendin-4 post-MI [34], many basic and clinical
studies are broadly supportive of persistent anti-inflam-
matory actions of GLP-1, including specific reduction of
TNF-a, IL-6, TLR-2/4, NF-jb, and MMP-9, which are key
drivers of cardiac remodelling [9, 17, 40]. Furthermore,
several studies report specific actions of GLP-1 on mac-
rophage function, supporting our suggestion that this rep-
resents the key inflammatory cell type underlying its
cardioprotective effects. For example, exendin-4 inhibits
monocyte adhesion in apoE-/- mice and suppresses LPS-
induced macrophage expression of pro-inflammatory
cytokines, whilst the DPP-4 inhibitor, sitagliptin, exerts
similar cAMP-dependent anti-inflammatory actions in
human macrophages and reduces macrophage-mediated
vascular inflammation in angiotensin II-infused apoE-/-
mice [2, 24, 26]. Of particular relevance to our study, a
GLP-1-producing recombinant adenovirus inhibits adipose
tissue macrophage infiltration and inflammation in ob/ob
diabetic mice [22]. Importantly, comparable effects have
been reported clinically, with the GLP-1R agonist,
liraglutide, decreasing circulating levels of the inflamma-
tory macrophage activation molecule, sCD163, in diabetic
patients [17].
It is becoming increasingly evident that inflammation
plays a key role in the pathogenesis of cardiac remodelling,
particularly in diabetes, and that macrophages may be
Fig. 6 Effect of exendin-4 on cardiac candidate cytokine and
chemokine expression after 4 weeks STZ diabetes. a–f Cytokine
and chemokine mRNA expression in LV tissue (n = 5–7). White
columns control; black columns exendin-4; mean ± SEM. *P\ 0.05
versus vehicle control; P\ 0.05 versus STZ control
1 Page 10 of 13 Basic Res Cardiol (2016) 111:1
123
critically involved. This putative role is supported by the
heterogeneous nature of monocyte/macrophage popula-
tions, which exhibit remarkable plasticity, allowing them to
alter physiological function in response to their microen-
vironment [29]. Notably, macrophages are involved
throughout the fibrotic response, during initiation, pro-
gression, and resolution, and it appears that distinct mac-
rophage populations exert both pro-fibrotic and anti-fibrotic
actions [47]. Indeed, stimulated macrophages induce IL-6
in cardiac fibroblasts and subsequent production of TGFb1
and Smad3 phosphorylation, thereby promoting myofi-
broblast differentiation both in vivo and in vitro [25],
providing support for macrophage–fibroblast communica-
tion as an important driver of cardiac remodelling. With
respect to our study, it is conceivable that specific modu-
lation of macrophage function by GLP-1 may underlie
many of its reported cardioprotective actions due to indi-
rect effects on the two primary effector cell types, ven-
tricular cardiomyocytes and fibroblasts, which do not
appear to express the GLP-1R, which is abundantly loca-
lised in monocytes and macrophages including mouse
BMDM employed in this study [34, 39, 44].
In this regard, we have previously reported that exendin-4
has no effect on cardiac myofibroblast differentiation in
normoglycemia, but does modulate basal macrophage
inflammatory gene expression and secretion [34]. Here, we
extended these findings to demonstrate that conditioned
media harvested from BMDM maintained in high glucose
was able to induce myofibroblast differentiation, which was
inhibited by exendin-4, highlighting paracrine communica-
tion between these cells as a potential target of GLP-1.
Notably, the concentration of exendin-4 used in these studies
(1 nmol/L) is equivalent to circulating levels typically found
in diabetic patients receiving exenatide [21]. Interestingly,
the inhibitory effect of exendin-4 on myofibroblast differ-
entiation was not observed in normoglycemia, which is
consistent with a previous report that the ex vivo infarct-
reducing actions of the DPP-4 inhibitors, sitagliptin and
vildagliptin, are only evident at elevated glucose concen-
trations ([7 mmol/L), with similar effects observed in vivo
in diabetic but not normoglycemic rats [15], suggesting that
the cardioprotective actions of GLP-1 may be glucose-de-
pendent. Although in vitro experimental models fail to
mimic the complex interactions that regulate cell signalling
in vivo, the findings of our complementary cell studies
appear to corroborate interpretation of our in vivo data in
suggesting that exendin-4 inhibits macrophage recruitment
to the diabetic heart and modulates subsequent paracrine
signalling, thereby reducing myofibroblast differentiation
and resultant ECM remodelling and diastolic dysfunction.
Importantly, of the cytokines/chemokines that were differ-
entially expressed/secreted by high glucose-treated BMDM
in response to exendin-4, several were also altered in cardiac
tissue from diabetic mice (e.g. CXCL10, IL-1b, and IL-10),
indicating that they may play a role in regulating ECM
remodelling. However, it should be noted that the in vivo
myocardial inflammatory response in diabetes is highly
complex and temporal in nature, so it is possible that some of
the identified mediators may not be relevant to the cardio-
protective effects of exendin-4, whilst others may have been
overlooked. Nonetheless, these data are clearly exciting in
highlighting potential cell-specific effects of exendin-4
which may underlie reduced cardiac remodelling in experi-
mental diabetes, and thereby warrant detailed further
investigation.
Taken together, our data indicate that exendin-4 specifi-
cally targets macrophage infiltration and function to reduce
adverse cardiac remodelling associated with experimental
diabetes. Whilst CHF in diabetic patients is an undoubted
multifactorial process, which is commonly associated with
ischemia and hypertension, it is clear that the diabetic milieu
is directly damaging to the heart and thereby makes a sig-
nificant contribution to disease progression. In this regard,
accumulating evidence implicates aberrant inflammation as
a key driver of pathogenic cardiac remodelling, particularly
in diabetes [19], so it is highly conceivable that inflamma-
tory pathways, such as those identified in this study, whose
activation precedes the development of contractile dys-
function and fibrosis, may represent potential therapeutic
targets. Although further work is clearly required to delin-
eate underlying mechanisms, our findings are clearly excit-
ing and suggest that selective cell-specific targeting of GLP-
1 signalling may represent a novel approach for the pre-
vention/treatment of CHF which is a major complication of
both type 1 and type 2 diabetes.
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